Merck KGaA to Open $326 Million Pharmaceutical Plant in South Korea to Expand in Asia
By David Sachs
Merck KGaA will spend more than 300 million euros ($326 million) on a pharmaceutical plant in South Korea as part of its strategy to expand in Asia.
The German drug-and-chemicals company said Wednesday that the plant will add 300 jobs. The Daejeon facility will serve biotech and pharmaceutical companies that develop, research and manufacture medical treatments like vaccines and cell, gene, and protein-based therapies, Merck said.
The production site will bring the firm closer to customers in an expanding market and should speed up the process of bringing new treatments from the development phase to commercialization, the firm said. Merck's investment is the largest to date by its life-sciences division in the Asia-Pacific region.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
March 20, 2024 11:42 ET (15:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks